AVE(SH:688067)2026-02-27 09:00Financial Performance - The company achieved total operating revenue of 230.03 million yuan, a year-on-year increase of 13.14%[4] - Net profit attributable to shareholders of the parent company reached 28.94 million yuan, up 26.72% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 23.07 million yuan, reflecting a significant increase of 47.91%[4] - Basic earnings per share were 0.43 yuan, representing a growth of 26.47% compared to the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were 580.15 million yuan, an increase of 3.41% from the beginning of the period[6] - Shareholders' equity attributable to the parent company was 514.43 million yuan, up 3.75% from the beginning of the period[5] Revenue Drivers - The increase in revenue was primarily driven by strong sales of reproductive tract secretion analyzers and related reagents, as well as the blood analysis production line launched in 2024[6] Cost Management - The company implemented cost control measures that resulted in a decrease in the main product costs, contributing to the higher net profit growth rate compared to revenue growth[6] Return on Assets - The weighted average return on net assets increased by 1.10 percentage points to 5.72%[4] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report as of the announcement date[9]